Apogee Therapeutics Inc.

Apogee Therapeutics Inc. is a clinical-stage biotechnology company developing differentiated biologics for inflammatory and immune diseases. It focuses on advancing novel antibody therapeutics targeting well-established biological drivers to address conditions with high unmet needs, including atopic dermatitis, chronic obstructive pulmonary disease, asthma, and other dermatological, respiratory, and gastroenterological disorders. The company's pipeline aims to improve treatment standards by optimizing antibodies for potentially superior efficacy and reduced dosing frequency compared to existing options. Apogee Therapeutics Inc. emphasizes creating therapies that enhance patient lives through innovative approaches in immunology. Its team consists of experienced clinical, commercial, scientific, and operational leaders committed to excellence in drug development. Headquartered in Waltham, Massachusetts, and founded in 2022, the company operates in the biotech sector dedicated to reshaping care for immune-mediated diseases.